CD34 and Alzheimer disease: Peaks from CD34+/monocyte-derived brain myeloid cells showed preferential enrichment for risk loci associated with multiple sclerosis, Alzheimer’s disease, intellectual disability, and depression in comparison to iHPCs peaks (Fig. 5l).